The Association of Community Cancer Centers is establishing two efforts targeted at improving cancer screening, care, and mortality rates for the Appalachian region of the U.S.
Researchers at The University of Texas MD Anderson Cancer Center identified a strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6.
Effective anti-vaping advertisements geared to teens have the greatest impact when they emphasize the adverse consequences and harms of vaping e-cigarettes, use negative imagery, and avoid memes, hashtags and other “teen-centric” communication styles, according to a study by researchers at UNC Lineberger Comprehensive Cancer Center.
The phase III SKYSCRAPER-01 did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
Initial results from the ANTLER phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) demonstrated a 100% overall response rate and 80% complete response rate in cohort 1 (n=5 evaluable).
The National Comprehensive Cancer Network added a prostate cancer test, IsoPSA, to its guidelines for early detection of the disease.
The American Society for Radiation Oncology issued an updated clinical guideline on the use of radiation therapy to treat patients with brain metastases, with the goal of supporting the multidisciplinary planning and delivery of advanced radiation therapy techniques to manage intact and resected brain metastases from non-hematologic solid tumors.
Cancer Research UK and the Stichting Oncode Institute, an independent research institute in the Netherlands, formed a strategic alliance focused on translating cancer research into benefits for patients.
RaySearch Laboratories AB and GE Healthcare said they are aiming to develop a radiation therapy simulation and treatment planning workflow solution. The companies said they plan on combining RaySearch’s advanced treatment planning system RayStation with GE Healthcare’s leading multi-modality (CT/MR/molecular imaging) simulator systems.
BridgeBio Pharma and Bristol Myers Squibb announced an exclusive license to develop and commercialize BBP-398, an SHP2 inhibitor, in oncology.
